EP3434280A4 - Rekombinanter hansenula-basierter hochdosierbarer hepatitis-b-impfstoff - Google Patents

Rekombinanter hansenula-basierter hochdosierbarer hepatitis-b-impfstoff Download PDF

Info

Publication number
EP3434280A4
EP3434280A4 EP17769367.8A EP17769367A EP3434280A4 EP 3434280 A4 EP3434280 A4 EP 3434280A4 EP 17769367 A EP17769367 A EP 17769367A EP 3434280 A4 EP3434280 A4 EP 3434280A4
Authority
EP
European Patent Office
Prior art keywords
hepatitis
high dosage
vaccine based
recombinant hansenula
hansenula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP17769367.8A
Other languages
English (en)
French (fr)
Other versions
EP3434280A1 (de
Inventor
Changhua WANG
Jun Yang
Hemu WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3434280A1 publication Critical patent/EP3434280A1/de
Publication of EP3434280A4 publication Critical patent/EP3434280A4/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01023—Orotidine-5'-phosphate decarboxylase (4.1.1.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/165—Yeast isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/78—Hansenula

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
EP17769367.8A 2016-03-25 2017-03-16 Rekombinanter hansenula-basierter hochdosierbarer hepatitis-b-impfstoff Ceased EP3434280A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610178526.8A CN105797151A (zh) 2016-03-25 2016-03-25 一种基于重组汉逊酵母的高剂量乙型肝炎疫苗
PCT/CN2017/076929 WO2017162090A1 (zh) 2016-03-25 2017-03-16 一种基于重组汉逊酵母的高剂量乙型肝炎疫苗

Publications (2)

Publication Number Publication Date
EP3434280A1 EP3434280A1 (de) 2019-01-30
EP3434280A4 true EP3434280A4 (de) 2019-10-30

Family

ID=56453918

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17769367.8A Ceased EP3434280A4 (de) 2016-03-25 2017-03-16 Rekombinanter hansenula-basierter hochdosierbarer hepatitis-b-impfstoff

Country Status (7)

Country Link
US (1) US10821174B2 (de)
EP (1) EP3434280A4 (de)
JP (3) JP6890174B2 (de)
CN (1) CN105797151A (de)
EA (1) EA201892169A1 (de)
SG (1) SG11201808268UA (de)
WO (1) WO2017162090A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105727280B (zh) * 2016-03-25 2021-01-19 汪和睦 基于表达HBsAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
CN105727279B (zh) * 2016-03-25 2019-01-15 汪和睦 基于表达HBsAg和HBcAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗
CN108715815A (zh) * 2018-05-30 2018-10-30 艾美汉信疫苗（大连）有限公司 一种基于重组汉逊酵母细胞技术高效培养、表达乙肝表面抗原的方法
CN118878648A (zh) * 2024-07-15 2024-11-01 大连理工大学 一种基因工程乙肝疫苗及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414374A2 (de) * 1989-07-25 1991-02-27 Smithkline Biologicals S.A. Antigene sowie Verfahren zu deren Herstellung
CN1651570A (zh) * 2004-09-30 2005-08-10 天津博荟生物技术有限公司 一种重组多形汉逊酵母菌及其构建方法与应用
CN101314761A (zh) * 2007-05-31 2008-12-03 上海生物制品研究所 高拷贝表达重组乙肝表面抗原的毕赤酵母及其制法和应用
US20140112954A1 (en) * 2011-05-16 2014-04-24 Dalian Hissen Bio-Pharm Co., Ltd. Method for preparing hbv vaccine comprising aluminum adjuvant
CN104232661A (zh) * 2013-06-08 2014-12-24 北京天坛生物制品股份有限公司 重组dna序列、酵母菌、乙肝表面抗原制备方法及疫苗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
CN104031926A (zh) * 2014-06-21 2014-09-10 段青姣 重组乙肝病毒、含有重组乙肝病毒基因的真核汉逊酵母工程菌及其制备方法和应用
CN104745492B (zh) * 2015-04-21 2018-10-30 南京赛威信生物医药有限公司 一种汉逊酵母突变体及其表达载体在重组蛋白表达方面的应用
CN105727280B (zh) * 2016-03-25 2021-01-19 汪和睦 基于表达HBsAg的热失活全重组汉逊酵母细胞的乙肝治疗疫苗

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414374A2 (de) * 1989-07-25 1991-02-27 Smithkline Biologicals S.A. Antigene sowie Verfahren zu deren Herstellung
CN1651570A (zh) * 2004-09-30 2005-08-10 天津博荟生物技术有限公司 一种重组多形汉逊酵母菌及其构建方法与应用
CN101314761A (zh) * 2007-05-31 2008-12-03 上海生物制品研究所 高拷贝表达重组乙肝表面抗原的毕赤酵母及其制法和应用
US20140112954A1 (en) * 2011-05-16 2014-04-24 Dalian Hissen Bio-Pharm Co., Ltd. Method for preparing hbv vaccine comprising aluminum adjuvant
CN104232661A (zh) * 2013-06-08 2014-12-24 北京天坛生物制品股份有限公司 重组dna序列、酵母菌、乙肝表面抗原制备方法及疫苗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CUNBAO LIU ET AL: "Diverse expression levels of two codon-optimized genes that encode human papilloma virus type 16 major protein L1 in Hansenula polymorpha", BIOTECHNOLOGY LETTERS, vol. 36, no. 5, 22 February 2014 (2014-02-22), Dordrecht, pages 937 - 945, XP055620163, ISSN: 0141-5492, DOI: 10.1007/s10529-014-1455-z *

Also Published As

Publication number Publication date
WO2017162090A1 (zh) 2017-09-28
JP2019512549A (ja) 2019-05-16
CN105797151A (zh) 2016-07-27
JP6890174B2 (ja) 2021-06-18
JP2022153550A (ja) 2022-10-12
EA201892169A1 (ru) 2019-07-31
US20190083608A1 (en) 2019-03-21
JP2021073261A (ja) 2021-05-13
US10821174B2 (en) 2020-11-03
SG11201808268UA (en) 2018-12-28
EP3434280A1 (de) 2019-01-30

Similar Documents

Publication Publication Date Title
EP3668522A4 (de) Wirksame mrna-impfstoffe
MA46766A (fr) Vaccin antigrippal
DK3609535T3 (da) Hbv-vaccine
IL263846B (en) Formulation of a peptide vaccine
EP3842529A4 (de) Antitumorvakzine auf exosombasis
LT3718565T (lt) Kvėpavimo takų virusų vakcinos
EP3577132A4 (de) Onkolytische virustherapie
EP3344291A4 (de) Impfstoffzusammensetzungen mit verbesserter stabilität und immunogenität
EP3672608A4 (de) Kräuterzusammensetzung mit verbesserter bioverfügbarkeit
EP4233846C0 (de) Pharmazeutische formulierungen
EP3385286A4 (de) Impfstoffantigen mit erhöhter immunogenität
EP3148566C0 (de) Synthetische, lange peptide (slp) zur therapeutischen impfung gegen hepatitis-b-virusinfektion
IL279537A (en) Aav compositions
EP3727445C0 (de) Hepatitis b virus (hbv) impfstoff und verwendung
HUE055231T2 (hu) Inzulint tartalmazó gyógyászati készítmények
IL291601A (en) Neoglycoconjugates as vaccines and therapeutic tools
EP3528827A4 (de) Influenza-hämagglutinin-protein-impfstoffe
EP3538542A4 (de) Gegen alpha-4beta-7-integrin gerichtete cyclische peptid-multimere
DK3244920T5 (da) Mund- og klovsyge-vaccine
EP3522872A4 (de) Amlodipinformulierungen
EP3434280A4 (de) Rekombinanter hansenula-basierter hochdosierbarer hepatitis-b-impfstoff
EP3434281A4 (de) Impfstoff zur behandlung von hepatitis-b auf basis von inaktivierten, vollständig rekombinanten hansenula-zellen mit expression von hbsag
DK3274447T3 (da) Rekombinant fåresygevirus jeryl lynn 2 baseret vaccine
EP3416727A4 (de) Verbesserte interferontherapie
EP3515929A4 (de) Therapeutische impfstoffe gegen hepatitis b

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181025

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191002

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 1/19 20060101ALI20190926BHEP

Ipc: A61K 39/39 20060101ALI20190926BHEP

Ipc: C12R 1/78 20060101ALI20190926BHEP

Ipc: A61P 31/20 20060101ALI20190926BHEP

Ipc: C07K 14/02 20060101ALI20190926BHEP

Ipc: A61K 39/29 20060101AFI20190926BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20211020

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20240115